Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-0456 | Other Identifier | Institutional Review Board | |
| A539300 | Other Identifier | UW Madison | |
| SMPH\RADIOLOGY\RADIOLOGY | Other Identifier | UW Madison | |
| NCI-2018-00466 | Registry Identifier | NCI Trial ID | |
| 06-08-2020 | Other Identifier | Protocol Version Date |
Not provided
Not provided
Not provided
Slow accrual following suspension per COVID-19
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this research is to determine the accuracy of PSMA positron emission tomography (PET) and multi-parametric magnetic resonance (MR) imaging to detect the presence of gynecological cancer cells in the body.
The investigators will evaluate a novel second-generation low-molecular-weight prostate specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL, to determine the presence or absence of cancer, the accurate distribution of cancer and the normal biodistribution of PSMA in the abdomen and pelvis on PET imaging.
PSMA, also known as folate hydrolase 1 and glutamate carboxypeptidase II, is an enzyme associated with prostate cancer but has been also found to be expressed in the tumor neovasculature of many different types of non-prostate cancer tumors. PSMA-based 18F-DCFPyL PET demonstrates very high tumor-to-background ratio when studied in other tumors, including prostate tumors.
MR imaging is a highly sensitive and specific imaging modality that can be used for gynecologic cancers. MR images can be obtained in conjunction with PSMA PET, adding additional anatomic and multi-parametric MRI information without the need for a second imaging appointment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Control Non-Dosimetry Group | Other | The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6 |
|
| Patient Group | Other | The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40 |
|
| Dosimetry Group | Other | Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PSMA-based 18F-DCFPyL PET tracer | Drug | PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic Accuracy | Estimate the frequency with which PSMA PET and MR imaging and final IHC staining disagree in their classifications of presence of disease. | up to 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Biodistribution of PSMA Measured by SUVmax in Normal Tissue | Record the normal biodistribution of PSMA as detected in normal tissue controls, by the resulting PET imaging. | up to 1 day |
| Biodistribution of PSMA Measured by SUVmax in Cancer Tissue |
Not provided
Inclusion Criteria for healthy female controls N=12 (includes up to 6 Dosimetry participants):
Inclusion Criteria for female controls (Dosimetry):
Inclusion Criteria for gynecological cancer patients (N=40):
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steve Cho, MD | University of Wisconsin, Madison | Principal Investigator |
| Elizabeth Sadowski, MD | University of Wisconsin, Madison | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Wisconsin, Madison | Madison | Wisconsin | 53705 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36512649 | Derived | Kunikowska J, Bizon M, Pelka K, Derlatka P, Olszewski M, Krolicki L. 68 Ga-Prostate-Specific Membrane Antigen PET/CT in Ovarian Tumors : Potential to Differentiate Benign and Malignant Tumors Before Surgery: A Preliminary Report. Clin Nucl Med. 2023 Feb 1;48(2):e60-e66. doi: 10.1097/RLU.0000000000004486. Epub 2022 Nov 18. |
| Label | URL |
|---|---|
| University of Wisconsin Carbone Cancer Center | View source |
Not provided
Not provided
15 participants were consented from November 2017 to December 2019. Research was suspended in March 2020 per the COVID-19 pandemic. The study opened to enrollment again in June 2022; there were no more participants consented. The investigator terminated the study in January 2023 due to slow accrual of patients with ovarian cancer and due to lack of funding. No participants were enrolled in the Dosimetry group.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healthy Control Non-Dosimetry Group | The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
| FG001 | Patient Group | The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
| FG002 | Dosimetry Group | Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
study terminated early, no participants enrolled in dosimetry group
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healthy Control Non-Dosimetry Group | The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Diagnostic Accuracy | Estimate the frequency with which PSMA PET and MR imaging and final IHC staining disagree in their classifications of presence of disease. | Calculating accuracy relies on the IHC staining as the gold standard. IHC staining was not done because the study was terminated due to low recruitment and loss of funds. Because the IHC staining was not performed, there is no gold standard by which to perform accuracy, sensitivity and specificity analysis. | Posted | up to 1 day |
|
during research visit, up to 3 hours
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healthy Control Non-Dosimetry Group | The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
Not provided
Not provided
Calculating accuracy, sensitivity and specificity relies on the IHC staining as the gold standard. IHC staining was not done because the study was terminated due to low recruitment and loss of funds. Because the IHC staining was not performed, there is no gold standard by which to perform accuracy, sensitivity and specificity analysis.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Elizabeth Sadowski, MD | UW School of Medicine and Public Health | 608-263-9028 | esadowski@uwhealth.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 8, 2020 | May 10, 2023 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Record the biodistribution of PSMA as detected in cancer tissue, by the resulting PET imaging.
| up to 1 day |
| Radiodosimetry of PSMA | The radiodosimetry of PSMA-based 18F-DCFPyL will be measured in normal female controls via the resulting PET images. | up to 1 day |
| Sensitivity and Specificity of PSMA-based PET/MR | Record the distribution of PSMA in cancer tissue. | up to 1 day |
| BG001 | Patient Group | The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Suspected Participant Diagnosis | Count of Participants | Participants |
|
| OG001 | Patient Group | The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
| OG002 | Dosimetry Group | Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer |
|
| Secondary | Biodistribution of PSMA Measured by SUVmax in Normal Tissue | Record the normal biodistribution of PSMA as detected in normal tissue controls, by the resulting PET imaging. | This was performed on the entire population of patients recruited in both the Healthy Control and Patient group. | Posted | Mean | Standard Deviation | SUVmax | up to 1 day |
|
|
|
| Secondary | Biodistribution of PSMA Measured by SUVmax in Cancer Tissue | Record the biodistribution of PSMA as detected in cancer tissue, by the resulting PET imaging. | This was performed on the "Patient" population. There was only one patient with confirmed ovarian cancer with PSMA uptake. | Posted | Mean | Standard Deviation | SUVmax | up to 1 day |
|
|
|
| Secondary | Radiodosimetry of PSMA | The radiodosimetry of PSMA-based 18F-DCFPyL will be measured in normal female controls via the resulting PET images. | No data was collected for this. There were no participants enrolled into the Dosimetry group. The study was terminated early due to low accrual and loss of funding. | Posted | up to 1 day |
|
|
| Secondary | Sensitivity and Specificity of PSMA-based PET/MR | Record the distribution of PSMA in cancer tissue. | Calculating sensitivity and specificity relies on the IHC staining as the gold standard. IHC staining was not done because the study was terminated due to low recruitment and loss of funds. Because the IHC staining was not performed, there is no gold standard by which to perform accuracy, sensitivity and specificity analysis. | Posted | up to 1 day |
|
|
| 0 |
| 2 |
| 0 |
| 2 |
| 0 |
| 2 |
| EG001 | Patient Group | The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40 PSMA-based 18F-DCFPyL PET tracer: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer | 0 | 12 | 0 | 12 | 0 | 12 |
Not provided
Not provided
Not provided
| D014591 |
| Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D004701 | Endocrine Gland Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
| Endometrial Cancer |
|
| Cervical Cancer |
|
| Other Cancer |
|
| Liver - Right Lobe |
|
|
| Myometrium |
|
|
| Endometrium |
|
|
| Cervix |
|
|
| Right Ovary |
|
|
| Corpus Luteum |
|
|
| Left Ovary |
|
|